Note 7 ? Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table as of June30, 2016: Total 2017 2018 2019 2020 2021 Thereafter Prescription Database $ 1,902,000 $ 731,000 $ 598,000 $ 573,000 $ - $ - $ - Natesto 8,500,000 6,000,000 - - 2,500,000 - - Manufacturing agreement 3,000,000 2,000,000 500,000 500,000 - - - Service agreement 204,000 204,000 - - - - - Primsol 750,000 750,000 - - - - - Office Lease 317,000 142,000 145,000 30,000 - - - Sponsored research agreement with related party 70,000 70,000 - - - - - $ 14,743,000 $ 9,897,000 $ 1,243,000 $ 1,103,000 $ 2,500,000 $ - $ - Prescription Database In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately $ 1,902,000 over three years for access to the database of prescriptions written for Natesto. Natesto In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $ 8,000,000 for the exclusive U.S. rights to Natesto of which $ 6,000,000 is payable in fiscal year 2017. Additionally, Aytu is required to make the first milestone payment even if the milestone is not reached. Manufacturing Agreement On October 8, 2015, Aytu and Biovest International, Inc., or Biovest, entered into a Master Services Agreement, pursuant to which Biovest is to provide manufacturing services to us for ProstaScint. In conjunction with entering into the agreement, we submitted a work order to Biovest to provide us with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $ 5.0 million, of which we paid $ 1.0 million upon submission of the work order and $ 500,000 in each of January and April 2016. We will pay an additional $ 2,000,000 in fiscal 2017, and $ 500,000 in both fiscal 2018 and 2019. Service Agreement In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $ 30,000 per month for shared overhead which includes costs